Panels
5903 Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis
shape book
ebook

Development of specific multiplexed immunofluorescence immune assays to study mouse models of tumorigenesis

Register here for download

Relevant for

Collaboration, FixVUE, InSituPlex

Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5816 Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
shape Monitor
webinar
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Length: 46 minutes

Relevant for

FixVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Webinar Learning Objectives

A better understanding of tumor heterogeneity, its immune environment and contextual relationship requires the spatial quantification of different immune and tumor cells along with the genetic background of the individual cancer.

The utilization of scRNA-seq and multiplexed Immunofluorescence techniques on NSCLC tumors to identify three main populations of intratumoral B and plasma cells.

An overview on the availability of digital tools in histopathology to allow interpreting the high-dimensional complexity of the spatial and immunological heterogeneity in tissue and integrating big (molecular) data to select the best and most effective treatment including combination and advanced therapies.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5848 Spatial multi-omics analysis targeting protein and RNA biomarkers on a single FFPE tissue section using an integrated staining and imaging workflow
shape poster
poster

Presented at: AACR 2022

Spatial multi-omics analysis targeting protein and RNA biomarkers on a single FFPE tissue section using an integrated staining and imaging workflow

Register here for download

Relevant for

FixVUE, InSituPlex, RNA scope

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Authors

Gourab Chatterjee, Grace Vezeau, Milena Lazova, Michael Sismour and Mael Manesse

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5829 Improved Understanding of the Biology and Pathophysiology of the TME in PDAC Samples Revealed by Both InSituPlex and Imaging Mass Cytometry
shape poster
poster

Presented at: AACR 2022

Improved Understanding of the Biology and Pathophysiology of the TME in PDAC Samples Revealed by Both InSituPlex and Imaging Mass Cytometry

Register here for download

Relevant for

Collaboration, FixVUE, Imaging mass cytometry, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Authors

Gourab Chatterjee, Grace Vezeau, Milena Lazova, Michael Sismour and Mael Manesse

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5814 The power of data analytics in biomarker programs
shape Monitor
webinar
Moritz Widmaier, PhD

Senior Product Manager AI & Data Analytics

The power of data analytics in biomarker programs

Length: 10 minutes

Relevant for

FixVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5796 Introduction to Ultivue’s capabilities for immuno-oncology biomarker programs
shape Monitor
webinar
Moritz Widmaier, PhD; Branden Hopkinson, PhD

Senior Product Manager AI & Data Analytics

Introduction to Ultivue’s capabilities for immuno-oncology biomarker programs

Length: 20 minutes

Relevant for

FlexVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Meet the hosts

Moritz will drill his way through whatever intellectual challenge you’ll put in front of him. He previously perforated biochemistry, image analysis, data science, immuno-oncology biomarkers, product management/ownership. He’ll condense the best of our ideas into a coherent roadmap. His product backlog will guide us towards our vision one step at a time.

Author
Moritz Widmaier, PhD

Senior Product Manager AI & Data Analytics

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5788 Gaining key phenotypic data from the tumor microenvironment using 8-plex immunofluorescence staining and image analysis
shape Monitor
webinar
Angela Vasaturo, PhD; Lorcan Sherry, PhD

Associate Director, Scientific Affairs Ultivue; Chief Science Officer, OracleBio

Gaining key phenotypic data from the tumor microenvironment using 8-plex immunofluorescence staining and image analysis

Length: 60 minutes

Relevant for

FixVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Lorcan is an image analysis expert who previously spent 10 years in the pharmaceutical industry as a group leader (Organon, Schering-Plough, Merck & Co.). He led a group responsible for performing histology, immunohistochemistry / image analysis and he has considerable experience in developing translational biomarker strategies for projects across various therapeutic areas. He is a Prince 2® qualified project manager and has extensive experience in study management.

Author
Lorcan Sherry, PhD

Chief Science Officer, OracleBio

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5786 FlexVUE for research
shape Monitor
webinar
Bonnie Philips, PhD

Senior Manager, FAS, North America

FlexVUE for research

Length: 20 minutes

Relevant for

FlexVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5808 UltiStacker for mIF
shape Monitor
webinar
Doug Wood, PhD

Principal Software Engineer

UltiStacker for mIF

Length: 17 minutes

Relevant for

FixVUE, FlexVUE, InSituPlex, U-VUE

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5784 FlexVUE for biomarker programs
shape Monitor
webinar
Angela Vasaturo, PhD

Associate Director Scientific Affairs

FlexVUE for biomarker programs

Length: 20 minutes

Relevant for

FlexVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5793 Introduction to FlexVUE
shape Monitor
webinar
Yvette Cajigas, ASCP

Senior Scientists, Product Development

Introduction to FlexVUE

Length: 11 minutes

Relevant for

FlexVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5826 Unique Insights into PDAC Development Revealed by Both InSituPlex and Imaging Mass Cytometry
shape poster
poster

Presented at: AACR 2022

Unique Insights into PDAC Development Revealed by Both InSituPlex and Imaging Mass Cytometry

Register here for download

Relevant for

Collaboration, FixVUE, Imaging mass cytometry, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Authors

Gourab Chatterjee, Grace Vezeau, Milena Lazova, Michael Sismour and Mael Manesse

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5725 Characterizing spatial distribution of immune-cell subsets in Nonalcoholic Steatohepatitis and Primary Sclerosing Cholangitis using a novel 12-plex Ultimapper ® kit
shape poster
poster

Presented at: AACR 2022

Characterizing spatial distribution of immune-cell subsets in Nonalcoholic Steatohepatitis and Primary Sclerosing Cholangitis using a novel 12-plex Ultimapper ® kit

Register here for download

Relevant for

FixVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Authors

Gourab Chatterjee, Grace Vezeau, Milena Lazova, Michael Sismour and Mael Manesse

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5818 Design and application of an 8-plex multiplex immunofluorescence panel for deep phenotypic profiling of the tumor microenvironment using InSituPlex technology
shape poster
poster

Presented at: AACR 2022

Design and application of an 8-plex multiplex immunofluorescence panel for deep phenotypic profiling of the tumor microenvironment using InSituPlex technology

Register here for download

Relevant for

Collaboration, FixVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: 5801 Multidimensional Multiplexing for Spatially Resolved Immune Tumor Heterogeneity
shape Monitor
webinar
Ralf Huss MD, PhD

Senior Field Applications Scientist, Ultivue

Multidimensional Multiplexing for Spatially Resolved Immune Tumor Heterogeneity

Length: 55 minutes

Relevant for

FixVUE, InSituPlex

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Meet the host

Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.

She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.

Author
Jennifer Giltnane MD, PhD

Principal Pathologist-Scientist, Genentech

Want to meet with us? Check out our upcoming events.

Want to meet with us? Check out our upcoming events.

Categories: